- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Interventions
- ampreloxetine, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 20
- States / cities
- Sun City, Arizona • La Jolla, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced May 21, 2026, 10:00 PM EDT